---
title: "Jupiter Neurosciences, Inc. (JUNS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/JUNS.US.md"
symbol: "JUNS.US"
name: "Jupiter Neurosciences, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T19:16:44.246Z"
locales:
  - [en](https://longbridge.com/en/quote/JUNS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/JUNS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/JUNS.US.md)
---

# Jupiter Neurosciences, Inc. (JUNS.US)

## Company Overview

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson’s disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer’s disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [jupiterneurosciences.com](https://jupiterneurosciences.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: E (0.81)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 185 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -175.25% |  |
| P/B Ratio | -4.17 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 11610000.64 |  |
| Revenue | 40448.00 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -6529.17% | E |
| Profit Margin | -22690.83% | E |
| Gross Margin | 76.61% | A |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | -175.25% | E |
| Total Assets YoY | -20.44% | E |
| Net Assets YoY | -190.83% | E |
| Cash Flow Margin | 63.01% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.01 | E |
| Gearing Ratio | 170.49% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jupiter Neurosciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-175.25%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-4.17",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "11610000.64",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "40448.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-6529.17%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-22690.83%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "76.61%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-175.25%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-20.44%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-190.83%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "63.01%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "170.49%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.26 | 115/189 | - | - | - |
| PB | -4.17 | 216/189 | 533.63 | 41.07 | 15.88 |
| PS (TTM) | 287.04 | 156/189 | 663.84 | 613.07 | 567.62 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-08-22T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.21 |
| Highest Target | 30.00 |
| Lowest Target | 30.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/JUNS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/JUNS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/JUNS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/JUNS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**